Swep Bio, Inc. — SEC Form D Filing

Swep Bio, Inc. filed an SEC Form D on October 29, 2026, reporting $2.50M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 29, 2026
Amount reported
$2.50M
Round stage
Seed stage, as Swep Bio has raised $2.5 million of an initial equity offering to support early R&D and foundational operations.
Industry
Biotechnology
Website
https://www.swepbio.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional therapeutic pipelines struggle to rapidly identify and validate novel biological targets for complex diseases.

Solution

Swep Bio develops targeted biopharmaceutical therapeutics to treat critical unmet medical conditions.

Why now

Recent advancements in molecular biology and high-throughput screening allow early-stage biotech companies to rapidly translate biological insights into therapeutic candidates.

Source: SEC EDGAR Form D filing